TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A study published November 4 in Neurology found that longer reproductive lifespan and some histories of hormone use were associated with fewer MRI signs of cerebral small vessel disease in women aged 70. The observational findings do not show that hormones caused the differences, and researchers say more study is needed.
A study published November 4 in Neurology found that longer reproductive lifespan and a history of using birth control pills or menopausal hormone therapy were associated with certain healthier brain blood-vessel measures among 352 women aged 70. The researchers stress that the results show associations, not that hormone exposure caused better brain health.
The study examined reproductive factors that may relate to lifetime estrogen exposure. Researchers defined reproductive lifespan as the years between a participant’s first menstrual period and menopause or surgical removal of the ovaries. The women had an average reproductive lifespan of 37 years. Researchers also recorded whether participants had used oral contraceptives or menopausal hormone therapy.
Brain MRI scans taken at ages 70 and 75 were assessed for four signs of cerebral small vessel disease: white matter hyperintensities, microbleeds, lacunes and moderate-to-severe enlargement of spaces around blood vessels. Each participant received a score from zero to four, based on how many signs were present.
After adjusting for selected factors, longer reproductive lifespan was associated with 8% lower odds of having two or more signs of the disease. In a separate analysis, past or current menopausal hormone therapy use was associated with a 59% lower risk of greater disease burden, including fewer microbleeds and enlarged spaces around vessels. Hormone therapy and oral contraceptive use were also associated with greater integrity of white matter microstructure, which the study describes as an early marker of healthier brain tissue.
Hormones and Small Vessel Health
Cerebral small vessel disease affects tiny blood vessels in the brain and is associated with stroke, cognitive impairment and dementia. The findings add vascular brain measures to research on how reproductive and hormonal histories may relate to brain aging, an area the study report says has received less attention than other aspects of women’s later-life brain health.
The results could help researchers identify questions for future studies, including whether hormone exposure at different life stages is associated with later vascular changes. They do not show that taking birth control pills or menopausal hormone therapy prevents small vessel disease, dementia or stroke. The study was observational, and its findings should not be used to infer that an individual should start, stop or change hormone treatment.
Products Worth Considering
Traeger Woodridge Pro Wood Pellet Grill and Smoker, 970 sq. in.
De'Longhi Classic Signature Espresso Machine with Adjustable Milk Frother
Weber Searwood XL 600 Wood Pellet Smoker Grill, 36 inches, Black
As an affiliate, we earn on qualifying purchases.
How Researchers Measured Exposure
Women are affected by Alzheimer’s disease more often than men, and the report notes that changing estrogen levels over a lifetime may be one factor relevant to brain health. Estrogen has been described as having protective effects on neurons and blood vessels, but its possible role in women’s cerebrovascular health later in life remains understudied. That biological context is a rationale for research, not proof that estrogen explains the study’s results.
At the study’s start, participants were 70 years old and did not have cognitive impairment. Seventy-three percent reported having used birth control pills, and 61% had used or were currently using menopausal hormone therapy. The strongest reported results came from distinct adjusted analyses: one considered factors including education, pregnancies and breastfeeding duration; another included factors such as education, high blood pressure and heart disease.
Researchers also reported that women who had used oral contraceptives and later received menopausal hormone therapy had the most favorable measures among the groups compared. Study author Anna Marseglia, of Karolinska Institutet in Stockholm, said this pattern points to a possible association across different life stages. It does not establish that sequential use produced the observed differences.
Limits of the Evidence
The study cannot show that longer reproductive lifespan or hormone use directly led to healthier MRI measures. The researchers said clinical trials would be needed to test cause and effect. The source report does not provide enough detail to determine whether the observed associations would apply to other populations or translate into fewer strokes, cognitive problems or dementia cases.
Hormone exposure was reported by participants in interviews, so some may not have recalled it accurately. Researchers could not follow individual hormone levels over time and lacked detailed information about the participants’ oral contraceptive and hormone therapy use. The study included cisgender women, and limited information on gender identity means the findings may not apply to all women. The report also does not establish which dose, timing or duration of hormone use might relate to the observed measures.
Further Research Needed
The study report does not announce a specific follow-up study or trial. Its findings point to the need for research that measures hormone exposure more precisely over time and examines whether the associations persist in larger or more diverse groups. Clinical trials would be needed to assess whether hormone treatment itself changes brain vascular outcomes, rather than simply being associated with them.
For now, the reported results are evidence of a relationship in this study population, not a treatment recommendation. Researchers and readers will need further evidence on how reproductive history relates to long-term vascular and cognitive outcomes, and whether any observed MRI differences have meaningful effects on health.
Key Questions
What did the study find?
In 352 women aged 70, longer reproductive lifespan and some histories of hormone use were associated with fewer signs of cerebral small vessel disease or healthier white matter measures on MRI. The study did not establish that hormones caused those differences.
What is cerebral small vessel disease?
It is a condition affecting tiny blood vessels in the brain. It is associated with stroke, cognitive impairment and dementia. The study assessed MRI signs including white matter hyperintensities, microbleeds, lacunes and enlarged spaces around blood vessels.
Does this mean hormone therapy prevents dementia or stroke?
No. The research was observational and assessed associations with MRI measures; it did not show that hormone therapy prevents dementia, stroke or small vessel disease.
What were the main limitations?
Hormone history was self-reported, hormone levels were not tracked over time, and details about treatment use were limited. The study population also limits how broadly the findings can be applied.
Who took part in the study?
The study included 352 women who were 70 and had no cognitive impairment at the start. Researchers noted that participants were cisgender women and that limited gender-identity information may restrict the findings’ relevance to other groups.
Source: news-medical.net
